CC-90011, a potent and reversible oral LSD1 inhibitor, was well tolerated in 50 patients with solid tumors (49) and relapsed/refractory (R/R) non-Hodgkin lymphoma (1) with thrombocytopenia being the most common adverse events reported (40%) (214). Here, KDM1A is linked to Thrombocytopenia.